Nanocarriers-based therapeutic strategy for drug-resistant epilepsy: A systematic review

[Display omitted] •Antiseizure drug-loaded nanocarriers mitigate seizures and associated alterations.•Nanocarriers show low toxicity in vivo and in vitro.•Nanocarriers exhibit promising biological properties for effective drug delivery. Nanocarriers have been proposed as a solution for drug-resistan...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2025-01, Vol.668, p.124986, Article 124986
Main Authors: Diaz-Peregrino, Roberto, San-Juan, Daniel, Patiño-Ramirez, Carlos, Sandoval-Luna, Lenin V., Arritola-Uriarte, Aleida
Format: Article
Language:English
Subjects:
Animals
Anticonvulsants - administration & dosage
Anticonvulsants - chemistry
Drug Carriers - chemistry
Drug Resistant Epilepsy - drug therapy
Drug-resistant epilepsy
Epilepsy
Humans
Nanocarriers
Nanoparticles
Nanotechnology
Treatment
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] •Antiseizure drug-loaded nanocarriers mitigate seizures and associated alterations.•Nanocarriers show low toxicity in vivo and in vitro.•Nanocarriers exhibit promising biological properties for effective drug delivery. Nanocarriers have been proposed as a solution for drug-resistant epilepsy. A systematic review of animal and in vitro studies was conducted to evaluate the efficacy, toxicity, and biological properties of nanocarriers. Searches were performed in PubMed/Medline and Scopus from March 2023 to March 2024. Eighteen studies were identified: 2 in vitro, 9 in vivo, and 7 combined. While epilepsy models and seizure control assessments were consistent, there was variability in evaluating the potential toxicity of nanocarriers. Only one study did not show a reduction in brain inflammation, seizures, and cell loss. Nanocarrier toxicity was evaluated just in six studies, all of which indicated low toxicity both in vitro and in vivo. Nanocarriers with antiseizure drugs manage seizures, inflammation, oxidative stress, and behavior impairment in drug-resistant epilepsy. Furthermore, nanocarriers are a safe option for delivering antiseizure drugs, though more research is needed to confirm these findings.
ISSN:0378-5173
1873-3476
1873-3476
DOI:10.1016/j.ijpharm.2024.124986